history of glp 1 drugs The evolution weight loss drugs: from dangers to GLP-1 blockbusters | BioKnow posted on the topic Continued growth for GLP-1 receptor
Description
GLP-1 analogues have completely changed this bleak therapeutic picture
Semaglutides STEP-1 trial landed at 14.9 percent over 68 weeks, and tirzepatides SURMOUNT-1 hit 20.9 percent at its top dose over 72 weeks
What don't we know
Victoza (liraglutide), the first GLP-1 for type 2 diabetes to lose exclusivity in June 2024, may not generate significant savings due to its once-daily dosing and limited market share
Conclusion A Time for Perspective The public health need for safe, effective, and affordable obesity treatment has never been more apparent
